Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Miscommunicating Risk: The Byetta Disconnect

This article was originally published in The Pink Sheet Daily

Executive Summary

Disconnect between level of warning FDA chose and financial markets’ reaction is an object lesson in the risks of risk communication.

You may also be interested in...



Groundhog Day For Byetta, GLP-1 Class: Is Regulatory Winter Nearly Over?

Sponsors of GLP-1 diabetes therapies and their investors are eagerly awaiting spring for greater clarity about the prospects of the antidiabetic class

Groundhog Day For Byetta, GLP-1 Class: Is Regulatory Winter Nearly Over?

Sponsors of GLP-1 diabetes therapies and their investors are eagerly awaiting spring for greater clarity about the prospects of the antidiabetic class

Amylin, Lilly Partnership Tested By Lilly GLP-1 Project

Amylin expects to discuss changes to its partnership agreement with Lilly if Lilly's internal GLP-1 antidiabetic compound LY2189265 continues to progress in the clinic

Topics

UsernamePublicRestriction

Register

LL009864

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel